The cost effectiveness of adalimumab (HUMIRA®) in UK patients with moderate to severe RA

被引：0
|
作者：
Bansback, NJ
Brennan, A
Sengupta, N
Pang, F
机构：
[1] Univ Sheffield, Sheffield, S Yorkshire, England
[2] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：512 / 513
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain
    Trigo-Vicente, Cristina
    Gimeno-Ballester, Vicente
    Montoiro-Allue, Raquel
    Lopez-Del Val, Alejandro
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (03) : 321 - 329
  • [32] Effect of adalimumab (humira®) on response to influenza virus and pneumococcal vaccines in patients with rheumatoid arthritis (RA)
    Kaine, J.
    Kivitz, A.
    Birbara, C.
    Luo, A. Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 304 - 304
  • [33] Rates of serious infections from adalimumab (HUMIRA®) clinical trials of patients with Rheumatoid Arthritis (RA)
    Kent, J. D.
    Pangan, A. L.
    Spencer-Green, G. T.
    Szczerbak, N.
    Sasso, E. H.
    RHEUMATOLOGY, 2006, 45 : I42 - I43
  • [34] LONG-TERM EFFECTIVENESS AND SAFETY OF ADALIMUMAB IN PATIENTS WITH MODERATE VERSUS SEVERE RHEUMATOID ARTHRITIS
    Burmester, G.
    Matucci-Cerinic, M.
    Navarro-Blasco, F.
    Oezer, U.
    Kary, S.
    Unnebrink, K.
    Kupper, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 365 - 365
  • [35] LONG-TERM EFFECTIVENESS AND SAFETY OF ADALIMUMAB IN PATIENTS WITH MODERATE VS SEVERE RHEUMATOID ARTHRITIS
    Burmester, Gerd R.
    Matucci-Cerinic, Marco
    Navarro-Blasco, Francisco
    Kary, Sonja
    Unnebrink, Kristina
    Kupper, Hartmut
    RHEUMATOLOGY, 2013, 52 : 81 - 81
  • [36] COST-EFFECTIVENESS OF TOCILIZUMAB COMPARED TO STANDARD THERAPEUTIC SEQUENCES FOR THE TREATMENT OF MODERATE/SEVERE RHEUMATOID ARTHRITIS (RA) PATIENTS IN PORTUGAL
    Diamantopoulos, A.
    Andrade, S.
    Bernardo, A.
    Branco, J.
    Ines, L.
    Pereira da Silva, J. A.
    Santos, M. J.
    Monteiro, I
    VALUE IN HEALTH, 2011, 14 (07) : A307 - A307
  • [37] Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan
    Chen, Der-Yuan
    Hsu, Ping-Ning
    Tang, Chao-Hsiun
    Claxton, Lindsay
    Valluri, Satish
    Gerber, Robert A.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (08) : 777 - 787
  • [38] Cost per responder of apremilast versus etanercept, adalimumab, and ustekinumab in patients with moderate to severe psoriasis
    Feldman, Steven R.
    Tencer, Tom
    Clancy, Zoe
    Zhang, Frank
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB229 - AB229
  • [39] Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain
    Trigo-Vicente, Cristina
    Gimeno-Ballester, Vicente
    Lopez-Del Val, Alejandro
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2020, 27 (06) : 355 - 360
  • [40] Two-year results of realise-a postmarketing observational study:: Effectiveness and safety of adalimumab (humira®) is maintained in patients with rheumatoid arthritis (ra)
    Burmester, G. R.
    Cerinic, M. Matucci
    Mariette, X.
    Blasco, F. Navarro
    Oezer, U.
    Jaeger, M.
    Kupper, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 165 - 165
12345